ABOUT US
Our Mission, Our Team, and Our Work
Rarity PBC is a mission-driven biotechnology company dedicated to developing life-saving treatments for rare genetic diseases.
As a Public Benefit Corporation, Rarity balances purpose and growth, prioritizing social impact alongside performance.
By combining innovation with a commitment to accessibility and equity, Rarity advances groundbreaking therapies while keeping patients and their families at the heart of every decision.
WHAT WE DO
Rarity PBC develops and delivers life-changing gene therapies for rare genetic diseases that have been overlooked by traditional biotech. Our flagship program, RDP-101, delivers a one-time stem cell gene therapy for ADA-SCID, a rare and life-threatening immune disorder.
Prioritizing restorative healthcare over traditional sick-care, Rarity develops affordable, transformative treatments to address critical unmet needs.
OUR MISSION
At Rarity, our mission is to transform the lives of individuals with rare genetic conditions by
developing life-saving therapies that are accessible, equitable, and sustainable.
We envision a future where no therapy for a rare disease is left undeveloped and every patient has access to life-changing care.
MEET OUR TEAM
.jpg)
Paul Ayoub, PhD
Chief Executive Officer
Co-founder
.jpg)
Katelyn Masiuk, MD PhD
Chief Scientific Officer
Co-founder
Roger Hollis, PhD
Viral Vector Advisor
Co-founder
Donald B Kohn, MD
Scientific Development Advisor
Co-founder
ADVISORY BOARD
Our Advisory Board consists of members with entrepreneurial, scientific, economic, and manufacturing experience all within the gene therapy space.
.jpg)
Andrea Spezzi, M.D
Business & Clinical
Development
Anne-Virginie Eggimann, MsC
Regulatory Development
Claire Booth, PhD, MsC
Clinical & Scientific Development
Terry Pirovolakis
Patient Access &
Business Development